AU775332B2 - Novel phosphorus-containing prodrugs - Google Patents

Novel phosphorus-containing prodrugs Download PDF

Info

Publication number
AU775332B2
AU775332B2 AU38658/00A AU3865800A AU775332B2 AU 775332 B2 AU775332 B2 AU 775332B2 AU 38658/00 A AU38658/00 A AU 38658/00A AU 3865800 A AU3865800 A AU 3865800A AU 775332 B2 AU775332 B2 AU 775332B2
Authority
AU
Australia
Prior art keywords
group
aryl
substituted
atoms
chr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU38658/00A
Other languages
English (en)
Other versions
AU3865800A (en
Inventor
Serge H. Boyer
Mark D Erion
K. Raja Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of AU3865800A publication Critical patent/AU3865800A/en
Application granted granted Critical
Publication of AU775332B2 publication Critical patent/AU775332B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65848—Cyclic amide derivatives of acids of phosphorus, in which two nitrogen atoms belong to the ring
AU38658/00A 1999-03-05 2000-03-03 Novel phosphorus-containing prodrugs Expired AU775332B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12301399P 1999-03-05 1999-03-05
US60/123013 1999-03-05
US15312799P 1999-09-08 1999-09-08
US60/153127 1999-09-08
PCT/US2000/005672 WO2000052015A2 (en) 1999-03-05 2000-03-03 Novel phosphorus-containing prodrugs

Publications (2)

Publication Number Publication Date
AU3865800A AU3865800A (en) 2000-09-21
AU775332B2 true AU775332B2 (en) 2004-07-29

Family

ID=26821130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38658/00A Expired AU775332B2 (en) 1999-03-05 2000-03-03 Novel phosphorus-containing prodrugs

Country Status (19)

Country Link
EP (2) EP1165570B9 (de)
JP (1) JP5063837B2 (de)
CN (1) CN1321999C (de)
AT (1) ATE337324T1 (de)
AU (1) AU775332B2 (de)
CA (1) CA2362805A1 (de)
CY (1) CY1105799T1 (de)
CZ (1) CZ20013180A3 (de)
DE (1) DE60030263T2 (de)
DK (1) DK1165570T3 (de)
ES (1) ES2272268T3 (de)
HK (1) HK1043796B (de)
HU (1) HUP0200260A3 (de)
IL (2) IL145052A0 (de)
MX (1) MXPA01008937A (de)
NZ (1) NZ513728A (de)
PT (1) PT1165570E (de)
SK (1) SK12442001A3 (de)
WO (1) WO2000052015A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6752981B1 (en) 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
ATE350385T1 (de) 2000-03-08 2007-01-15 Metabasis Therapeutics Inc Neue aryl fructose-1,6-bisphosphatase inhibitoren
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
WO2003059921A1 (en) * 2002-01-18 2003-07-24 Leo Pharma A/S Mmp inhibitors
EP1532157A4 (de) 2002-05-13 2009-02-25 Metabasis Therapeutics Inc Neue prodrugs von pmea auf phosphonsäurebasis und ihre analoga
EP1504014B1 (de) 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Verfahren zur herstellung zyklischer prodrugs von pmea und pmpa
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MXPA05004504A (es) 2002-10-31 2005-08-16 Metabasis Therapeutics Inc Nuevos di-esteres de fosfato ciclicos de 1,3-propano-1-aril-dioles y su uso en la preparacion de profarmacos.
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
EP1678322A2 (de) * 2003-10-24 2006-07-12 Gilead Sciences, Inc. Verfahren und zusammensetzungen zur identifizierung therapeutischer verbindungen
MXPA06006899A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c.
EP1753762B1 (de) 2004-06-08 2014-03-19 Metabasis Therapeutics, Inc. Lewissäurevermittelte synthese von cyclischen estern
ME01945B (me) 2004-07-27 2011-12-31 Gilead Sciences Inc Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
US7932240B2 (en) * 2007-08-31 2011-04-26 Idenix Pharmaceuticals, Inc. Phosphadiazine HCV polymerase inhibitors IV
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
CN102089318B (zh) 2008-07-08 2014-05-21 吉里德科学公司 Hiv抑制剂化合物的盐
WO2010036613A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741300A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
EP2538784B1 (de) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazolderivate als antidiabetika
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
JP2018529681A (ja) * 2015-09-10 2018-10-11 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ シクロホスファミド及びイホスファミドのイムノアッセイ用の免疫原及びアッセイ接合体として用いるシクロホスファミド類似体
CN106565626B (zh) * 2016-10-10 2022-06-10 淮海工学院 2-氨基-4-芳基-5-甲硫基噻唑类化合物的合成方法
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
CN117405433A (zh) 2017-09-21 2024-01-16 贝克顿·迪金森公司 危险污染物收集试剂盒和快速测试
MX2020009843A (es) 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
WO2019213153A1 (en) * 2018-04-30 2019-11-07 Unity Biotechnology Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2019213526A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
CN111434671B (zh) * 2019-01-11 2023-07-11 凯思凯迪（上海）医药科技有限公司 肝脏特异性ampk激动剂及其制法和应用
EP3918300A4 (de) 2019-01-28 2022-11-16 Becton, Dickinson and Company Schadstoffsammelvorrichtung mit integriertem tupfer und testvorrichtung

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE563332A (de) * 1956-12-20
CH492738A (de) * 1967-09-13 1970-06-30 Sandoz Ag Verfahren zur Herstellung von 2-(Bis-(2-chloräthyl)aminophenyl-4- -amino)-2H-1,3,2-oxazaphosphorin-tetrahydro-2-oxid
DE2752125A1 (de) * 1977-11-22 1979-05-23 Max Planck Gesellschaft Neue phosphororganische ringverbindungen, ihre herstellung und verwendung
DE3132221A1 (de) * 1981-08-14 1983-05-19 Behringwerke Ag, 3550 Marburg Neue cyclophosphamid-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE3133077A1 (de) * 1981-08-21 1983-03-10 Henkel KGaA, 4000 Düsseldorf Neue cytostatisch wirksame epoxidgruppen tragende 1,3,2-oxazaphosphorin-verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung in pharmazeutischen zubereitungen
EP0158057B1 (de) * 1984-03-01 1989-04-26 ASTA Pharma AG Neue Salze von Oxazaphosphorin-Derivaten
FR2562543B1 (fr) 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US4757141A (en) * 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
DE3600289A1 (de) * 1986-01-08 1987-07-09 Bayer Ag Cyclische malonylphosphonsaeurediamide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
EP0353692B1 (de) * 1988-08-02 1995-10-04 Nissan Chemical Industries Ltd. Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
DE69129650T2 (de) * 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
AU1164597A (en) * 1995-12-19 1997-07-14 Darwin Discovery Limited Ifosfamide, analogues thereof and their preparation
JPH09241284A (ja) * 1996-03-08 1997-09-16 Koji Yamashita 新規なオキシアザホスホリン誘導体
GB9618634D0 (en) * 1996-09-06 1996-10-16 Univ Southampton Anti cancer drugs
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6110903A (en) * 1997-03-07 2000-08-29 Sankyo Company Ltd. Benzimidazole inhibitors of fructose 1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU761267C (en) * 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Also Published As

Publication number Publication date
WO2000052015A3 (en) 2001-02-15
DE60030263T2 (de) 2007-08-30
EP1165570A2 (de) 2002-01-02
EP1165570B1 (de) 2006-08-23
JP2002538161A (ja) 2002-11-12
HUP0200260A3 (en) 2002-11-28
JP5063837B2 (ja) 2012-10-31
HK1043796B (zh) 2007-02-23
ES2272268T3 (es) 2007-05-01
IL145052A0 (en) 2002-06-30
MXPA01008937A (es) 2004-04-05
HUP0200260A2 (en) 2002-06-29
WO2000052015A2 (en) 2000-09-08
CN1321999C (zh) 2007-06-20
EP1724276A1 (de) 2006-11-22
ATE337324T1 (de) 2006-09-15
CA2362805A1 (en) 2000-09-08
IL145052A (en) 2007-07-24
DK1165570T3 (da) 2006-12-18
CY1105799T1 (el) 2011-02-02
AU3865800A (en) 2000-09-21
NZ513728A (en) 2001-09-28
EP1165570B9 (de) 2007-02-21
CN1353719A (zh) 2002-06-12
HK1043796A1 (en) 2002-09-27
DE60030263D1 (de) 2006-10-05
CZ20013180A3 (cs) 2002-02-13
PT1165570E (pt) 2007-01-31
SK12442001A3 (sk) 2002-06-04

Similar Documents

Publication Publication Date Title
AU775332B2 (en) Novel phosphorus-containing prodrugs
US8664195B2 (en) Phosphorus-containing prodrugs
US6312662B1 (en) Prodrugs phosphorus-containing compounds
EP1060182B1 (de) Neue prodrugs für phosphorhaltige verbindungen
US6752981B1 (en) Prodrugs for liver specific drug delivery
EP1634886A2 (de) Neue Phosphor enthaltende Medikamentenvorläuferverbindungen
CN100494208C (zh) 新的含磷前药
AU2004200670B2 (en) Novel Prodrugs for Phosphorous-containing Compounds

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired